S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica

DDG · 2025 · Germany

Source and licence

Authors
Cornelia Erfurt‐Berge, Regina Renner, Melanie Peckruhn et al.
Title
S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica
Journal
Journal Der Deutschen Dermatologischen Gesellschaft, 2025
Licence
CC BY 4.0
Changes
Verbatim excerpts; formatting adapted

Full text retrieved 2026-10-27 from Europe PMC · PMC12968943

Licence statement of the original publication

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.

Open the original publication →Full text on Europe PMC

Recommendations

We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.

Abstract

Necrobiosis lipoidica (NL) is a rare granulomatous skin disease of unknown etiology that occurs frequently in association with diabetes mellitus and other comorbidities. The predilection site is the lower leg, particularly the pretibial areas. The exact pathogenesis remains unclear. Vascular disorders with microangiopathic changes and an autoimmune genesis are discussed. Necrobiosis lipoidica occurs three to six times more frequently in women. Men tend to show a more severe course and develop ulcerations more frequently. The diagnosis can often be established based on typical clinical and dermatoscopic findings. A biopsy should be performed in clinically unclear cases, in the presence of ulceration, or if there are signs of malignant transformation. Overall, the scientific data available for NL are still insufficient and there is a need for further research. However, as patients often experience a severely impaired quality of life, it is important to be aware of the limited scientific evidence and to translate it into practical therapeutic recommendations. This short version of the S1 guideline of the German Dermatological Society (DDG) summarizes the current evidence and, incorporating expert assessments, provides specific recommendations for everyday clinical practice.

Contents of the original publication

The section headings of the original.

  • INTRODUCTION
  • PATHOGENESIS
  • DIAGNOSTICS AND CLINICAL COURSE
  • HISTOLOGY
  • DIFFERENTIAL DIAGNOSES
  • ASSOCIATED DISEASES
  • TREATMENT
  • Topical treatments
  • Glucocorticoids
  • Tacrolimus (off label)
  • LIGHT AND LASER TREATMENTS
  • UV therapies
  • Other physical therapies
  • Compression therapy
  • Surgical treatment
  • Wound treatment in ulcerated necrobiosis lipoidica
  • Systemic treatments
  • Systemic glucocorticoids
  • Fumaric acid esters (off label)
  • Ciclosporin (off label)
  • Antimalarial medications (off label)
  • Biologicals (off label)
  • Janus kinase inhibitors (off label)
  • Other systemic treatment approaches (off label)
  • Special considerations in children and adolescents
  • Limitations of this guideline
  • Clinical practice summary

A question about this guideline?

Medelix answers clinical questions from guidelines and studies – every statement with its source.

Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint